Regeneron (Nasdaq: REGN) and Sanofi (NYSE: SNY) announced that the European Commission (EC) has granted marketing authorization for Praluent (alirocumab) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE